Key result
Captopril monotherapy was associated with no change from baseline in physical symptom distress over 24 weeks, comparing favorably to methyldopa and propranolol which increased specific symptoms.
Why the study?
Does captopril compared to methyldopa or propranolol reduce physical symptom distress in male hypertensive patients?
RCT (n=761)
Does captopril compared to methyldopa or propranolol reduce physical symptom distress in male hypertensive patients?
Captopril is associated with less physical symptom distress compared to methyldopa and propranolol in male hypertensive patients, highlighting its value in preserving quality of life and potentially preventing noncompliance.
No takes yet. Share an insight, caveat, or question.
Supports captopril for lower symptom distress versus older agents in hypertension; extends randomized evidence favoring ACE inhibitors on tolerability.
Schoenberger et al. (1990) conducted an RCT in Hypertension (n=761). Captopril vs. Methyldopa or propranolol was evaluated on Distress associated with physical symptoms. Captopril monotherapy was associated with no change from baseline in physical symptom distress over 24 weeks, comparing favorably to methyldopa and propranolol which increased specific symptoms.
Synapse has enriched one closely related paper. Consider it for comparative context: